🔎 Trials Near Me

Beranda › Kanker Metastatik › Ohio › Cincinnati

Uji klinis Kanker Metastatik di Cincinnati, OH

20 studi untuk Kanker Metastatik mencari peserta di lokasi sekitar Cincinnati (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Menerima pesertaFase 2
  • Good Samaritan Hospital - Cincinnati, Cincinnati
Semua usia · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05564377

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

Menerima pesertaFase 1
  • University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
  • University of Cincinnati Cancer Center-West Chester, West Chester · 15 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT05803382

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Menerima pesertaFase 3
  • Oncology Hematology Care - Eastgate, Cincinnati
  • Oncology Hematology Care Clinical Trials, LLC, Fairfield · 15 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07222800

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Menerima pesertaFase 3
  • Oncology Hematology Care Clinical Trials, Cincinnati
  • Oncology Hematology Care Clinical Trials, Cincinnati
  • Oncology Hematology Care Clinical Trials, Cincinnati
  • dan 1 lainnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07222566

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Menerima pesertaFase 3
  • University of Cincinnati Medical Center, Cincinnati
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07218380

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Menerima pesertaFase 3
  • Saint Elizabeth Medical Center Edgewood, Edgewood · 8 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07174336

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Menerima pesertaFase 3
  • University of Cincinnati Medical Center, Cincinnati
  • Oncology Hematology Care Inc, Cincinnati
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07213804

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

Menerima pesertaFase 3
  • Research Site, Edgewood · 8 mi jauhnya
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT07647328

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Menerima pesertaFase 3
  • USO - Oncology Hematology Care, Cincinnati
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06119581

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Menerima pesertaFase 2
  • St. Elizabeth Healthcare, Edgewood · 8 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT06769698

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

Menerima pesertaFase 1
  • University of Cincinnati Medical Center (UCMC), Cincinnati
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT05614739

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Menerima pesertaFase 1/2
  • Oncology Hematology Care Primary, Cincinnati
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT04657068

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

Menerima pesertaFase 3
  • Research Site, Cincinnati
Usia 18 ke atas · Wanita · Diperbarui 29 Jul 2026 · NCT07044336

A Study of PYX-201 in Advanced Solid Tumors

Menerima pesertaFase 1
  • University of Cincinnati Medical Center, Cincinnati
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jun 2026 · NCT05720117

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Menerima pesertaFase 1
  • The Christ Hospital, Cincinnati
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Jun 2026 · NCT06040541

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Menerima pesertaFase 1/2
  • Christ Hospital Cancer Center, Cincinnati
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Mei 2026 · NCT05379985

Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

Menerima pesertaFase 2
  • University of Cincinnati Medical Center, Cincinnati
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Mei 2026 · NCT06416007

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Menerima pesertaStudi observasional
  • Massive Bio SYNERGY-AI site, Cincinnati
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

Menerima pesertaFase 1
  • The Christ Hospital Cancer Center, Cincinnati
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2025 · NCT05808634

Uji klinis Kanker Metastatik di kota lain

Studi lain di Cincinnati

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.